Quick Answer
Arcus Biosciences, Inc. reported Diluted EPS of $3.29 per share (loss) for fiscal year 2025.
Arcus Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.29 | -4.8% |
| 2024 | -$3.14 | +24.3% |
| 2023 | -$4.15 | -11.9% |
| 2022 | -$3.71 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.27 | -27.0% | — |
| June 30, 2025 | $0.00 | +100.0% | +100.0% |
| March 31, 2025 | -$1.14 | -2180.0% | -14.0% |
| September 30, 2024 | -$1.00 | -6.4% | +2.0% |
| June 30, 2024 | -$1.02 | +1.9% | -1940.0% |
| March 31, 2024 | -$0.05 | +95.4% | +94.7% |
| September 30, 2023 | -$0.94 | — | +9.6% |
| June 30, 2023 | -$1.04 | — | +4.6% |
- Arcus Biosciences, Inc. showed a decrease of -4.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Arcus Biosciences, Inc.’s diluted eps has grown by 11.3% (from $3.71 per share (loss) to $3.29 per share (loss)).
- The most recent figure is from Arcus Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: